Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Bernard Zinman's publication output changed over time?
ScholarIQpublication output · 2006–2019
Output declined50% over the shown period — from 2 works in 2006 to 1 in 2019.
2
1
1
1
3
2
1
1
20062007200820152016201720182019
What are the most-cited papers on Bernard Zinman?
ScholarIQmost cited works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi
New England Journal of Medicine. 201512,121 CitationsOPEN ACCESS
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen, Peter Lommer Kristensen, Johannes F.E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R Poulter, Lasse Steen Ravn, William M. Steinberg, Mette Stockner, Bernard Zinman, Richard M. Bergenstal, John B. Buse
New England Journal of Medicine. 20167,491 CitationsOPEN ACCESS
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg Jardine, Bruce Neal, Séverine Bompoint, Hiddo J.L. Heerspink, David M. Charytan, Robert Edwards, Rajiv Agarwal, George L. Bakris, Scott Bull, Christopher P. Cannon, George Capuano, Pei-Ling Chu, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol A. Pollock, David C. Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Gary Meininger, Barry M. Brenner, Kenneth W. Mahaffey
New England Journal of Medicine. 20196,091 CitationsOPEN ACCESS
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin, Bernard Zinman
Diabetes Care. 20083,848 CitationsOPEN ACCESS
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Bernard Zinman
New England Journal of Medicine. 20163,655 CitationsOPEN ACCESS
Related on ScholarIQ
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Paper
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Paper
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Paper
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Paper
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Paper
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Paper